Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
about
Vaccine adjuvants: mode of actionToll-like receptors: the swiss army knife of immunity and vaccine developmentBeyond empiricism: informing vaccine development through innate immunity researchAge-dependent dysregulation of innate immunityNew vaccines against influenza virus.New technologies for influenza vaccines.Virus-like particles as universal influenza vaccinesAdapting global influenza management strategies to address emerging viruses.CD103-CD11b+ dendritic cells regulate the sensitivity of CD4 T-cell responses to bacterial flagellin.Role of aging on innate responses to viral infections.Fast vaccine design and development based on correlates of protection (COPs).TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon.Flagellin as carrier and adjuvant in cocaine vaccine development.Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly.Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates.Flagellin-dependent TLR5/caveolin-1 as a promising immune activator in immunosenescence.Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly.Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins.Traditional and new influenza vaccinesVaccine strategies to enhance immune responses in the aged.Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.Imaging murine NALT following intranasal immunization with flagellin-modified circumsporozoite protein malaria vaccines.Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization.Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathwayImmunization of patients with autoimmune inflammatory rheumatic diseases (the EULAR recommendations).Adjuvanted influenza vaccines.Assessing the safety of influenza vaccination in specific populations: children and the elderly.Salivary IgA enhancement strategy for development of a nasal-spray anti-caries mucosal vaccine.Bacterial flagellin-a potent immunomodulatory agent.Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection.Advances in Antiviral Therapies Targeting Toll-like Receptors.Functional properties of flagellin as a stimulator of innate immunity.The global challenge and future strategies for keeping the world's aging population healthy by vaccination.A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.Reduced dynamic range of antiviral innate immune responses in aging.Adjuvanting an inactivated influenza vaccine with flagellin improves the function and quantity of the long-term antibody response in a nonhuman primate neonate model.Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo.
P2860
Q21131210-B2205713-A1BB-45A5-A947-BA79AD9AC46BQ26746644-1737BAF3-74C4-4196-AE0C-A3C9A307E9E2Q26824573-C24AA3A7-F87C-42A7-B69A-4F3C5FEEE338Q27022410-7E5084AA-AFC7-4DF3-8219-D7D2D1961BFBQ30357932-61899BF6-ECC0-4C5E-8CC9-36C8AF6A0404Q30411859-04DC691A-11A6-40A9-8022-4269C8DD5EF7Q30421558-0774C511-7F4A-4B0F-939C-4E323184DBE3Q30431093-C1C0C45B-BA8C-4E04-9FCF-D198F24F75C0Q33654093-E07C8EE7-2468-4CA7-B7C3-146D2A1B0647Q34063443-92CFB28E-CCE3-4F38-8F16-D254F96D6DD3Q34291098-38633945-4872-4A9E-B547-A8DB1E4F1A62Q34414790-4F67B02C-4E32-4EE0-B692-BBC6AE297187Q34778787-669B87A9-D24C-44F9-B897-2FD9F1EA89C1Q35057556-986889A0-A7F3-4CD1-8B6E-BC8860AF438CQ35095954-29F4F410-9201-4CD3-8612-15AE363DDDCDQ35548048-FCB5D79F-385F-420D-B18F-E8ACB90A9562Q35670256-F5D9BF2C-09DE-4AEC-87BE-935BB5C19F77Q35758568-45BAECBC-797F-4F27-A641-16AF76060ACBQ36057679-1A47A1F4-443F-4B78-AEAC-C24270E68FA1Q36511529-6D798CCB-F35E-4691-BDE9-BC82DF63EF0EQ36615539-F3663841-53A7-4214-8872-0D037D65B334Q37035833-4E2F3865-161E-41BA-81C8-960EC5BE85A4Q37179398-D079CF23-1A2D-4BF7-91D8-CDAAFF8BF99DQ37336064-77435A63-683C-4D48-A377-B2ADACDA5DA0Q37446364-D5938FC3-25C4-44C1-97D0-4C20501C3180Q37505389-F584DD39-BED6-4029-801C-CA08976640F3Q37587048-22873446-5808-4D67-82A3-15B19864E993Q37974891-372427F8-EE37-4EAE-8B10-41B4540971CDQ37976540-7C10DB2E-E2F4-4675-AC3A-1D5BFD8F6E3CQ38045920-6220356B-C7D1-4D3B-8781-ABF5E243DF9EQ38103192-E7C76D02-4439-4F2A-8796-B863F1C6AF2DQ38634734-046CA065-5A4F-4400-AD83-D4A36E8282EDQ38678908-75425B0A-E373-4D89-AADE-2B9678D99504Q38733975-2FFD4731-6E99-4F34-B5EF-108E8762CEF7Q38804686-104031F6-0017-41F2-A30A-0C76073B67F8Q38822152-1988B379-F84F-4437-AB3B-1F187F6EC85FQ39698048-40B0A31C-9911-4D9B-89AF-C3EC002FAD8FQ40077623-5C154AAD-C2C6-47FA-AA40-032BF1CFB210Q40578582-17D52EE7-75B9-4A7A-935B-7C502DCDE6EAQ41717896-F3224B5B-1FE8-498E-B223-1D5455855E26
P2860
Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Induction of a potent immune r ...... vaccine (VAX125, STF2.HA1 SI).
@en
Induction of a potent immune r ...... vaccine (VAX125, STF2.HA1 SI).
@nl
type
label
Induction of a potent immune r ...... vaccine (VAX125, STF2.HA1 SI).
@en
Induction of a potent immune r ...... vaccine (VAX125, STF2.HA1 SI).
@nl
prefLabel
Induction of a potent immune r ...... vaccine (VAX125, STF2.HA1 SI).
@en
Induction of a potent immune r ...... vaccine (VAX125, STF2.HA1 SI).
@nl
P2093
P1433
P1476
Induction of a potent immune r ...... vaccine (VAX125, STF2.HA1 SI).
@en
P2093
Casey Johnson
Cynthia Strout
David N Taylor
John J Treanor
Karen Ozer
Lynda Tussey
Theresa Fitzgerald
Uma Kavita
P304
P356
10.1016/J.VACCINE.2011.05.001
P407
P577
2011-05-17T00:00:00Z